{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:24:17Z","timestamp":1790619857163,"version":"4.1.0"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T00:00:00Z","timestamp":1494633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      More effective therapies are emerging, with better toxicity profiles, and are being incorporated into modern treatment algorithms of chronic lymphocytic leukemia at various stages of the disease, including for patients harboring Del17p and\/or aberrant\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      . Ibrutinib, an inhibitor of Bruton\u2019s tyrosine kinase, has demonstrated impressive response rates in the relapsed\/refrac-tory setting, including in the setting of Del17p and\/or\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      mutations. Venetoclax, an inhibitor of\n                      <jats:italic toggle=\"yes\">BCL-2<\/jats:italic>\n                      known to play an important role in regulating cell death, has been approved recently for treatment of patients with chronic lymphocytic leukemia with Del17p who have received at least one prior therapy. Unfortunately, a cure remains unattainable unless eligible patients are offered an allogeneic hematopoietic cell transplant. However, hematopoietic cell allografting is limited by the availability of suitable donors and significant morbidity and mortality. Recent clinical practice recommendations by the American Society for Blood and Marrow Transplantation have relegated the role of transplantation to later stages of the disease. In patients with evidence of Richter syndrome, frontline consolidation allogeneic hematopoietic cell transplantation remains the most desirable approach owing to the limited activity of ibrutinib or other novel therapies. Further therapeutic advances would require enrolling these patients in large clinical trials that evaluate novel therapies alone or in combination with traditional chemotherapies or even in the setting of posttransplant consolidation\/maintenance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2017.04.002","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T00:17:54Z","timestamp":1495153074000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Del17p and\/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies"],"prefix":"10.4103","volume":"11","author":[{"given":"Hind","family":"Rafei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"A. Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2017.04.002_b0005","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.04.002_b0010","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.23671","article-title":"Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia","volume":"113","author":"Kharfan-Dabaja","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.04.002_b0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.hemonc.2017.04.002_b0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.04.002_b0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0030","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0035","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.04.002_b0040","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0045","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2012-11-469627","article-title":"TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial","volume":"121","author":"Dreger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0050","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.beha.2016.08.001","article-title":"Current state of hematopoietic cell transplantation in CLL as smart therapies emerge","volume":"29","author":"Kharfan-Dabaja","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bmt.2016.204","article-title":"Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL","volume":"52","author":"Khouri","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.04.002_b0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/107327481201900107","article-title":"Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens","volume":"19","author":"Kharfan-Dabaja","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.hemonc.2017.04.002_b0065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2007.06591.x","article-title":"Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia","volume":"137","author":"Khouri","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0070","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","article-title":"Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"22","author":"Kharfan-Dabaja","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.04.002_b0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0080","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.04.002_b0085","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLLIPIwg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0090","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hemonc.2017.04.002_b0095","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0100","first-page":"246","article-title":"Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis","volume":"6","author":"Fenaux","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.04.002_b0105","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0110","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V82.11.3452.3452","article-title":"P53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1\/MDR3 gene expression","volume":"82","author":"el Rouby","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0115","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1365-2141.2003.04336.x","article-title":"Mechanism of action of purine analogues in chronic lymphocytic leukaemia","volume":"121","author":"Pettitt","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0120","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1046\/j.1365-2141.1999.01649.x","article-title":"The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia","volume":"106","author":"Pettitt","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0125","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.hemonc.2017.04.002_b0130","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0135","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bjh.13824","article-title":"The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years","volume":"172","author":"Else","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0145","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0150","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/blood.V84.10.3440.3440","article-title":"Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs","volume":"84","author":"Silber","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10428199609054821","article-title":"Chlorambucil in chronic lymphocytic leukemia: mechanism of action","volume":"23","author":"Begleiter","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2017.04.002_b0160","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0165","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0170","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","article-title":"Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0175","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ajh.23391","article-title":"The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed\/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia","volume":"88","author":"Visco","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0185","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0190","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2009.133","article-title":"Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia","volume":"23","author":"Castro","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.04.002_b0195","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3324\/haematol.11903","article-title":"High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy","volume":"93","author":"Dungarwalla","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.04.002_b0200","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/leu.2008.214","article-title":"Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia","volume":"22","author":"Castro","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.04.002_b0205","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hemonc.2017.04.002_b0210","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0220","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0225","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/cncr.25028","article-title":"Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia","volume":"116","author":"Kay","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.04.002_b0230","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1200\/JCO.2009.22.0442","article-title":"Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia","volume":"27","author":"Bosch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0235","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-003-0710-5","article-title":"High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities","volume":"82","author":"Thornton","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0240","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.ejca.2010.04.021","article-title":"High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia","volume":"46","author":"Xu","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hemonc.2017.04.002_b0245","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.V128.22.2051.2051","article-title":"A phase Ib\/II study of combined obinutuzumab (Gazyva) and high-dose methylprednisolone (HDMP) as treatment for patients with chronic lymphocytic leukemia (CLL)","volume":"128","author":"Castro","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0250","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1182\/blood-2014-01-547737","article-title":"Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL","volume":"123","author":"Geisler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0255","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10428194.2014.910654","article-title":"Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes","volume":"56","author":"Frankfurt","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2017.04.002_b0260","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.2011.35.9695","article-title":"Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the National Cancer Research Institute CLL206 trial","volume":"30","author":"Pettitt","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0265","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/leu.2009.148","article-title":"Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study","volume":"23","author":"Cortelezzi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.04.002_b0270","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0275","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/cncr.25434","article-title":"Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.04.002_b0280","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.04.002_b0285","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0290","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hemonc.2017.04.002_b0295","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0300","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b\/2 study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0305","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjh.14447","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and\/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial","volume":"176","author":"Sharman","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0310","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia","volume":"125","author":"Brown","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0315","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.V128.22.641.641","article-title":"TGR-1202 in combination with ibrutinib in patients with relapsed or refractory CLL or MCL: preliminary results of a multicenter phase I\/Ib study","volume":"128","author":"Davids","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0320","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0325","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood.V128.22.233.233","article-title":"Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic leukemia","volume":"128","author":"O\u2019Brien","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0330","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia","volume":"126","author":"O'Brien","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0335","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000525","article-title":"Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides","volume":"39","author":"Louie","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0340","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","article-title":"Idelalisib-associated colitis: histologic findings in 14 patients","volume":"39","author":"Weidner","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0345","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0350","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.04.002_b0355","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0360","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.04.002_b0365","unstructured":"Pasquini M, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR summary slides; 2015. Available at: http:\/\/www.cibmtr.org."},{"key":"10.1016\/j.hemonc.2017.04.002_b0370","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0375","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.04.002_b0380","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0385","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.bbmt.2016.06.025","article-title":"Hematopoietic cell transplantation for Richter syndrome","volume":"22","author":"El-Asmar","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.04.002_b0390","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.04.002_b0395","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.04.002_b0400","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hemonc.2017.04.002_b0405","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201811010-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:48:48Z","timestamp":1787838528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201811010-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2017.04.002","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}